CA2422815A1 - Moyens et methodes de suivi d'une therapie antiretrovirale a base d'inhibiteurs de proteases et decisions d'orientation therapeutique dans le traitement du vih et du sida - Google Patents
Moyens et methodes de suivi d'une therapie antiretrovirale a base d'inhibiteurs de proteases et decisions d'orientation therapeutique dans le traitement du vih et du sida Download PDFInfo
- Publication number
- CA2422815A1 CA2422815A1 CA002422815A CA2422815A CA2422815A1 CA 2422815 A1 CA2422815 A1 CA 2422815A1 CA 002422815 A CA002422815 A CA 002422815A CA 2422815 A CA2422815 A CA 2422815A CA 2422815 A1 CA2422815 A1 CA 2422815A1
- Authority
- CA
- Canada
- Prior art keywords
- hiv
- mutation
- patient
- codon
- protease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 236
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title claims abstract description 130
- 238000011225 antiretroviral therapy Methods 0.000 title claims abstract description 46
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 title abstract description 70
- 238000011282 treatment Methods 0.000 title abstract description 31
- 238000012544 monitoring process Methods 0.000 title abstract description 7
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 238000012360 testing method Methods 0.000 claims abstract description 299
- 239000003814 drug Substances 0.000 claims abstract description 222
- 229940079593 drug Drugs 0.000 claims abstract description 222
- 230000035772 mutation Effects 0.000 claims description 449
- 239000013598 vector Substances 0.000 claims description 282
- 108090000623 proteins and genes Proteins 0.000 claims description 262
- 108020004705 Codon Proteins 0.000 claims description 198
- 108091005804 Peptidases Proteins 0.000 claims description 178
- 241000700605 Viruses Species 0.000 claims description 173
- 239000004365 Protease Substances 0.000 claims description 157
- 230000003612 virological effect Effects 0.000 claims description 126
- 229960001936 indinavir Drugs 0.000 claims description 108
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 108
- 150000007523 nucleic acids Chemical class 0.000 claims description 96
- 230000010076 replication Effects 0.000 claims description 95
- 235000001014 amino acid Nutrition 0.000 claims description 88
- 150000001413 amino acids Chemical class 0.000 claims description 87
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 79
- 229960000884 nelfinavir Drugs 0.000 claims description 79
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 79
- 102000039446 nucleic acids Human genes 0.000 claims description 78
- 108020004707 nucleic acids Proteins 0.000 claims description 78
- 239000000523 sample Substances 0.000 claims description 71
- 229960001830 amprenavir Drugs 0.000 claims description 69
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 69
- 229960001852 saquinavir Drugs 0.000 claims description 69
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 69
- 229940024606 amino acid Drugs 0.000 claims description 67
- 230000000798 anti-retroviral effect Effects 0.000 claims description 67
- 108010010369 HIV Protease Proteins 0.000 claims description 60
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 59
- 230000000694 effects Effects 0.000 claims description 58
- 150000001875 compounds Chemical class 0.000 claims description 55
- 239000012472 biological sample Substances 0.000 claims description 50
- 230000014509 gene expression Effects 0.000 claims description 50
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 48
- 238000006467 substitution reaction Methods 0.000 claims description 46
- 230000003247 decreasing effect Effects 0.000 claims description 43
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 40
- 239000002245 particle Substances 0.000 claims description 40
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 40
- 108060001084 Luciferase Proteins 0.000 claims description 38
- 239000005089 Luciferase Substances 0.000 claims description 36
- 230000001965 increasing effect Effects 0.000 claims description 36
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 32
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 32
- 239000004473 Threonine Substances 0.000 claims description 32
- 229940124522 antiretrovirals Drugs 0.000 claims description 32
- 238000005259 measurement Methods 0.000 claims description 31
- 229960000311 ritonavir Drugs 0.000 claims description 29
- 239000003903 antiretrovirus agent Substances 0.000 claims description 28
- 210000001072 colon Anatomy 0.000 claims description 27
- 230000009467 reduction Effects 0.000 claims description 26
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 24
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 24
- 235000004279 alanine Nutrition 0.000 claims description 23
- 229930182817 methionine Natural products 0.000 claims description 22
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 21
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 21
- 239000004474 valine Substances 0.000 claims description 21
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 19
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 18
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 18
- 238000012258 culturing Methods 0.000 claims description 18
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 16
- 230000001419 dependent effect Effects 0.000 claims description 16
- 108010002459 HIV Integrase Proteins 0.000 claims description 9
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- 150000001294 alanine derivatives Chemical class 0.000 claims description 4
- 238000003306 harvesting Methods 0.000 claims description 4
- 239000013643 reference control Substances 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 25
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 20
- 229960000310 isoleucine Drugs 0.000 claims 20
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 20
- 239000004475 Arginine Substances 0.000 claims 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 4
- 235000018417 cysteine Nutrition 0.000 claims 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 3
- 150000002742 methionines Chemical class 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 105
- 238000003239 susceptibility assay Methods 0.000 abstract description 34
- 239000003443 antiviral agent Substances 0.000 abstract description 24
- 208000015181 infectious disease Diseases 0.000 abstract description 24
- 208000030507 AIDS Diseases 0.000 abstract description 16
- 230000004044 response Effects 0.000 abstract description 9
- 208000031886 HIV Infections Diseases 0.000 abstract description 8
- 208000037357 HIV infectious disease Diseases 0.000 abstract description 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract description 5
- 238000011269 treatment regimen Methods 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 169
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 149
- 102100034347 Integrase Human genes 0.000 description 99
- 108020004414 DNA Proteins 0.000 description 98
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 77
- 235000019419 proteases Nutrition 0.000 description 75
- 230000002829 reductive effect Effects 0.000 description 65
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 63
- 239000013603 viral vector Substances 0.000 description 57
- 238000003752 polymerase chain reaction Methods 0.000 description 53
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 46
- 239000013610 patient sample Substances 0.000 description 46
- 238000004806 packaging method and process Methods 0.000 description 44
- 102200139516 rs35960830 Human genes 0.000 description 42
- 108091026890 Coding region Proteins 0.000 description 39
- 238000003556 assay Methods 0.000 description 39
- 239000013615 primer Substances 0.000 description 38
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 33
- 108020000999 Viral RNA Proteins 0.000 description 33
- 102200089571 rs104893827 Human genes 0.000 description 31
- 238000012163 sequencing technique Methods 0.000 description 30
- 239000000047 product Substances 0.000 description 29
- 230000002596 correlated effect Effects 0.000 description 28
- 230000007423 decrease Effects 0.000 description 27
- 238000002560 therapeutic procedure Methods 0.000 description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 description 22
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 238000003757 reverse transcription PCR Methods 0.000 description 21
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 21
- 239000013612 plasmid Substances 0.000 description 20
- 206010059866 Drug resistance Diseases 0.000 description 19
- 230000000840 anti-viral effect Effects 0.000 description 19
- 239000003112 inhibitor Substances 0.000 description 19
- 238000001890 transfection Methods 0.000 description 19
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 18
- 239000013604 expression vector Substances 0.000 description 18
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 18
- 108700005077 Viral Genes Proteins 0.000 description 17
- 238000012512 characterization method Methods 0.000 description 17
- 238000012545 processing Methods 0.000 description 17
- 102220057902 rs730881670 Human genes 0.000 description 17
- 238000002741 site-directed mutagenesis Methods 0.000 description 17
- 238000010804 cDNA synthesis Methods 0.000 description 16
- 230000010354 integration Effects 0.000 description 16
- 102220097967 rs876660873 Human genes 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 108020004635 Complementary DNA Proteins 0.000 description 14
- 238000010367 cloning Methods 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 14
- 230000002103 transcriptional effect Effects 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 13
- 238000013518 transcription Methods 0.000 description 13
- 230000035897 transcription Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 12
- 239000003623 enhancer Substances 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 11
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 10
- 108010061833 Integrases Proteins 0.000 description 10
- 239000006143 cell culture medium Substances 0.000 description 10
- 238000010276 construction Methods 0.000 description 10
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 10
- 229960003804 efavirenz Drugs 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 238000002955 isolation Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000010839 reverse transcription Methods 0.000 description 10
- 102220257505 rs61754178 Human genes 0.000 description 10
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 9
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 9
- 229960004748 abacavir Drugs 0.000 description 9
- 230000004075 alteration Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 229960005319 delavirdine Drugs 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 229960000689 nevirapine Drugs 0.000 description 9
- 102220067568 rs202141764 Human genes 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 241001430294 unidentified retrovirus Species 0.000 description 9
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 9
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 8
- 101710177166 Phosphoprotein Proteins 0.000 description 8
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 8
- 108091027544 Subgenomic mRNA Proteins 0.000 description 8
- 108010067390 Viral Proteins Proteins 0.000 description 8
- 230000036436 anti-hiv Effects 0.000 description 8
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- -1 hydroxyaminopentane amide Chemical class 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 8
- 229960002555 zidovudine Drugs 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- 108091035707 Consensus sequence Proteins 0.000 description 7
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 102220298202 rs1384593055 Human genes 0.000 description 7
- 102220080214 rs149830675 Human genes 0.000 description 7
- 238000011285 therapeutic regimen Methods 0.000 description 7
- 230000029812 viral genome replication Effects 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 101150038105 pr gene Proteins 0.000 description 6
- 230000001177 retroviral effect Effects 0.000 description 6
- 102200103620 rs121908920 Human genes 0.000 description 6
- 230000007501 viral attachment Effects 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 101710177291 Gag polyprotein Proteins 0.000 description 5
- 241000700721 Hepatitis B virus Species 0.000 description 5
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 5
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 5
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102200042996 rs1057521927 Human genes 0.000 description 5
- 102200037866 rs122454126 Human genes 0.000 description 5
- 102220038679 rs140987045 Human genes 0.000 description 5
- 102220271314 rs1555462506 Human genes 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 4
- 101100519162 Arabidopsis thaliana PCR6 gene Proteins 0.000 description 4
- 241000713838 Avian myeloblastosis virus Species 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 241001227713 Chiron Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000004544 DNA amplification Effects 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 101710170658 Endogenous retrovirus group K member 10 Gag polyprotein Proteins 0.000 description 4
- 101710186314 Endogenous retrovirus group K member 21 Gag polyprotein Proteins 0.000 description 4
- 101710162093 Endogenous retrovirus group K member 24 Gag polyprotein Proteins 0.000 description 4
- 101710094596 Endogenous retrovirus group K member 8 Gag polyprotein Proteins 0.000 description 4
- 101710177443 Endogenous retrovirus group K member 9 Gag polyprotein Proteins 0.000 description 4
- 241000710831 Flavivirus Species 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000581002 Murex Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 108010022394 Threonine synthase Proteins 0.000 description 4
- 108020005202 Viral DNA Proteins 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 230000010310 bacterial transformation Effects 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000012503 blood component Substances 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 4
- 230000001447 compensatory effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 108700004025 env Genes Proteins 0.000 description 4
- 101150030339 env gene Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001917 fluorescence detection Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 239000004030 hiv protease inhibitor Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 229940124524 integrase inhibitor Drugs 0.000 description 4
- 239000002850 integrase inhibitor Substances 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 230000001566 pro-viral effect Effects 0.000 description 4
- 102220005323 rs33946401 Human genes 0.000 description 4
- 102220077594 rs761906487 Human genes 0.000 description 4
- 102220229708 rs876660131 Human genes 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 3
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 3
- 108700020129 Human immunodeficiency virus 1 p31 integrase Proteins 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- 101710203526 Integrase Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 102220486474 Mannose-1-phosphate guanyltransferase beta_N37A_mutation Human genes 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 208000001388 Opportunistic Infections Diseases 0.000 description 3
- 102100034574 P protein Human genes 0.000 description 3
- 101710181008 P protein Proteins 0.000 description 3
- 108010076039 Polyproteins Proteins 0.000 description 3
- 102220595858 Protein RCC2_K20T_mutation Human genes 0.000 description 3
- 241000242743 Renilla reniformis Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 229940121357 antivirals Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 229960001714 calcium phosphate Drugs 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000000975 co-precipitation Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 102220288746 rs140563222 Human genes 0.000 description 3
- 102200158793 rs281864892 Human genes 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- ABAFKQHGFDZEJO-UHFFFAOYSA-N 4,6,6-trimethylbicyclo[3.1.1]heptane-4-carbaldehyde Chemical compound C1C2C(C)(C)C1CCC2(C)C=O ABAFKQHGFDZEJO-UHFFFAOYSA-N 0.000 description 2
- 241001128034 Amphotropic murine leukemia virus Species 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 108091062157 Cis-regulatory element Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 229940122440 HIV protease inhibitor Drugs 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 241000254158 Lampyridae Species 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 238000009004 PCR Kit Methods 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 108010010677 Phosphodiesterase I Proteins 0.000 description 2
- 241000218633 Pinidae Species 0.000 description 2
- 102220564795 Protein Lines homolog 1_K20M_mutation Human genes 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 241000557720 Thermus brockianus Species 0.000 description 2
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 2
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 102200027218 c.217G>A Human genes 0.000 description 2
- 102220360095 c.43A>G Human genes 0.000 description 2
- 101150055766 cat gene Proteins 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000008004 cell lysis buffer Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000012411 cloning technique Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 239000007771 core particle Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000002741 methionine derivatives Chemical class 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 101150009573 phoA gene Proteins 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 102220321537 rs1399717425 Human genes 0.000 description 2
- 102220282734 rs770335248 Human genes 0.000 description 2
- 102220095187 rs876658411 Human genes 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000035892 strand transfer Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- IHAIQFIIVUZFHC-IPIKRLCPSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1.OC(=O)[C@@H](N)CC1=CC=CC=C1 IHAIQFIIVUZFHC-IPIKRLCPSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- JJQGZGOEDSSHTE-FOHZUACHSA-N Asp-Thr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JJQGZGOEDSSHTE-FOHZUACHSA-N 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 231100000036 EC90 Toxicity 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229940126544 HIV-1 protease inhibitor Drugs 0.000 description 1
- 108700024845 Hepatitis B virus P Proteins 0.000 description 1
- 101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101150083678 IL2 gene Proteins 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 241000255893 Pyralidae Species 0.000 description 1
- 241001340896 Pyralis Species 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 102220490292 TGF-beta receptor type-2_M36V_mutation Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 102100037111 Uracil-DNA glycosylase Human genes 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010065648 Virologic failure Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 102220351589 c.28C>A Human genes 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 230000001036 exonucleolytic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 108700004028 nef Genes Proteins 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012247 phenotypical assay Methods 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940064914 retrovir Drugs 0.000 description 1
- 108700004030 rev Genes Proteins 0.000 description 1
- 102220032371 rs104895243 Human genes 0.000 description 1
- 102220199232 rs1057521120 Human genes 0.000 description 1
- 102220044567 rs142243299 Human genes 0.000 description 1
- 102220274636 rs144712084 Human genes 0.000 description 1
- 102220005402 rs33939421 Human genes 0.000 description 1
- 102220251169 rs368061837 Human genes 0.000 description 1
- 102220053718 rs573489857 Human genes 0.000 description 1
- 102220092383 rs750951965 Human genes 0.000 description 1
- 102220282908 rs772319724 Human genes 0.000 description 1
- 102220096705 rs876660327 Human genes 0.000 description 1
- 102220102437 rs878855252 Human genes 0.000 description 1
- 102220278876 rs977251189 Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000011450 sequencing therapy Methods 0.000 description 1
- 238000012883 sequential measurement Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 108700004027 tat Genes Proteins 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
- 108700026215 vpr Genes Proteins 0.000 description 1
- 108700026222 vpu Genes Proteins 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention porte sur des essais de susceptibilité et se résistance à des médicaments antiviraux servant à identifier des posologies efficaces pour le traitement d'infections par le VIH, et du SIDA, dont en particulier des posologies incluant un inhibiteur de protéase. L'invention porte également sur des moyens et procédés de suivi de la progression de l'infection par le VIH, et de sa réponse à une thérapie antivirale dans le cadre d'essais de susceptibilité aux phénotypes et génotypes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/663,458 | 2000-09-15 | ||
| US09/663,458 US7186506B1 (en) | 2000-06-12 | 2000-09-15 | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| PCT/US2001/028754 WO2002022076A2 (fr) | 2000-09-15 | 2001-09-14 | Moyens et methodes de suivi d'une therapie antiretrovirale a base d'inhibiteurs de proteases et decisions d'orientation therapeutique dans le traitement du vih et du sida |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2422815A1 true CA2422815A1 (fr) | 2002-03-21 |
Family
ID=24661900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002422815A Abandoned CA2422815A1 (fr) | 2000-09-15 | 2001-09-14 | Moyens et methodes de suivi d'une therapie antiretrovirale a base d'inhibiteurs de proteases et decisions d'orientation therapeutique dans le traitement du vih et du sida |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1322779A4 (fr) |
| AU (1) | AU2001290923A1 (fr) |
| CA (1) | CA2422815A1 (fr) |
| WO (1) | WO2002022076A2 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01012270A (es) | 1999-05-28 | 2003-06-24 | Virco Nv | Nuevos perfiles mutacionales en la transcriptasa reversa de vih-1 correlacionadas con resistencia fenotipica a farmacos. |
| US7186506B1 (en) | 2000-06-12 | 2007-03-06 | Monogram Biosciences, Inc. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| US6869759B1 (en) | 1999-06-22 | 2005-03-22 | Virologic, Inc. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| US7138231B2 (en) * | 2000-09-15 | 2006-11-21 | Monogram Biosciences, Inc. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| AU2631602A (en) | 2000-10-20 | 2002-04-29 | Virco Nv | New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| US7384734B2 (en) | 2002-02-15 | 2008-06-10 | Monogram Biosciences, Inc. | Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors |
| WO2004003223A2 (fr) | 2002-07-01 | 2004-01-08 | Tibotec Pharmaceuticals Ltd. | Nouveaux profils mutationnels dans une transcriptase inverse du vih-1 correles a une resistance phenotypique aux medicaments |
| DE60327768D1 (de) | 2002-07-01 | 2009-07-09 | Tibotec Pharm Ltd | Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease |
| TW200411180A (en) * | 2002-07-01 | 2004-07-01 | Virologic Inc | Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors |
| JP2006506967A (ja) | 2002-07-01 | 2006-03-02 | バイロロジック，インコーポレーテッド | プロテアーゼ阻害剤に対する病原性ウイルスの感受性を決定するための組成物および方法 |
| AU2008257703A1 (en) | 2007-05-25 | 2008-12-04 | Tibotec Pharmaceuticals | New mutational profile in HIV-1 Gag cleavage site correlated with phenotypic drug resistance |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0011939A (pt) * | 1999-06-22 | 2002-03-12 | Virologic Inc | Recursos e métodos para monitorar terapia anti-retroviral inibidora de protease e orientar decisões terapêuticas no tratamento de hiv/aids |
-
2001
- 2001-09-14 CA CA002422815A patent/CA2422815A1/fr not_active Abandoned
- 2001-09-14 WO PCT/US2001/028754 patent/WO2002022076A2/fr not_active Ceased
- 2001-09-14 EP EP01970982A patent/EP1322779A4/fr not_active Withdrawn
- 2001-09-14 AU AU2001290923A patent/AU2001290923A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002022076A3 (fr) | 2003-03-27 |
| AU2001290923A1 (en) | 2002-03-26 |
| EP1322779A4 (fr) | 2005-04-20 |
| WO2002022076A2 (fr) | 2002-03-21 |
| EP1322779A2 (fr) | 2003-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110229906A1 (en) | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS | |
| CA2375905A1 (fr) | Moyens et methodes pour surveiller un traitement antiretroviral utilisant un inhibiteur de la protease et pour aider a la prise de decisions therapeutiques concernant le traitement du vih/sida | |
| US7138231B2 (en) | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS | |
| CA2341679A1 (fr) | Methodes et moyens pour controler une therapie antiretrovirale utilisant l'inhibiteur de la reverse-transcriptase nucleosidique, et pour operer des choix therapeutiques dans le traitement du vih/sida | |
| US6653081B2 (en) | Methods for monitoring antiretroviral therapy and guiding therapeutic decision in the treatment of HIV/AIDS | |
| CA2422815A1 (fr) | Moyens et methodes de suivi d'une therapie antiretrovirale a base d'inhibiteurs de proteases et decisions d'orientation therapeutique dans le traitement du vih et du sida | |
| AU772511B2 (en) | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy | |
| WO2002099387A2 (fr) | Dispositif et methodes de surveillance d'une therapie antiretrovirale inhibitrice de la protease et determination de decisions therapeutiques dans le traitement du vih/sida | |
| US6869759B1 (en) | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS | |
| US6489098B1 (en) | Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS | |
| US7186506B1 (en) | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS | |
| US20050130134A1 (en) | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment HIV-AIDS | |
| CA2411401A1 (fr) | Systemes et procedes pour le controle de therapie antiretrovirale et l'orientation des decisions therapeutiques dans le traitement du vih/sida | |
| US7037644B1 (en) | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS | |
| AU2007231808A1 (en) | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS | |
| US20020094522A1 (en) | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20070914 |